Skip to main content

Advertisement

SpringerLink
Log in

Effectiveness and Complications of Anthracycline and Taxane in the Therapy of Breast Cancer: A Meta-analysis

  • Research
  • Published:
Pathology & Oncology Research

Abstract

Objective

To compare the efficacy and safety between anthracycline & taxane and anthracycline in the treatment of breast cancer.

Methods

Computer-assisted literature search was performed with PubMed, MEDLINE, EMBASE and Cochrane Controlled Trials Register (CCTR) to identify pertinent literatures. Software RevMan 5.0 was used for statistical analysis. The measurement of interest outcomes included severe neurotoxicity, death without breast cancer recurrences, leukemia, venous thrombus and severe cardiotoxicity.

Results

A total of 10 randomized controlled trial studies (RCTs) containing 18,198 cases were selected in this meta-analysis. Of which, 9,902 cases were treated with anthracycline & taxane and 8,296 cases treated with anthracycline alone as control. Anthracycline & taxane showed lower risks of incident leukemia (RR = 0.40; 95 % CI: 0.18, 0.90), venous thrombus (RR = 0.49; 95 % CI: 0.29, 0.84) and severe cardiotoxicity (RR = 0.41, 95%CI: 0.26, 0.66), but higher risks of incident severe neurotoxicity (RR = 5.97; 95 % CI: 1.72, 20.65) and non-recurrent death (RR = 1.79; 95 % CI: 1.06, 3.04), compared to anthracycline alone.

Conclusion

Clinically important differences exist for general safety in favour of the anthracycline & taxane rather than anthracycline alone. However, as a result of tumor recurrent rate, anthracycline might be superior to anthracycline & taxane. A longer duration of follow-up and a larger number of cases are required to better assess the efficacy and safety profile of the treatment of breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57(1):43–66

    Article  PubMed  Google Scholar 

  2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci 100(7):3983–3988

    Article  CAS  PubMed  Google Scholar 

  3. De Laurentiis M, Cancello G, D’Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26(1):44–53

    Article  PubMed  Google Scholar 

  4. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, Blohmer JU, Eiermann W, Jackesz R, Jonat W, Lebeau A, Loibl S, Miller W, Seeber S, Semiglazov V, Smith R, Souchon R, Stearns V, Untch M, von Minckwitz G (2006) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24(12):1940–1949. doi:10.1200/JCO.2005.02.6187

    Article  PubMed  Google Scholar 

  5. Kaufmann M, von Minckwitz G, Rody A (2005) Preoperative (neoadjuvant) systemic treatment of breast cancer. Breast 14(6):576–581. doi:10.1016/j.breast.2005.08.010

    Article  PubMed  Google Scholar 

  6. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, Isola J (2000) Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156(3):839–847

    Article  CAS  PubMed  Google Scholar 

  7. Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, Hannon GJ, Lowe SW, Hemann MT (2008) Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A 105(26):9053–9058. doi:10.1073/pnas.0803513105

    Article  PubMed Central  PubMed  Google Scholar 

  8. Trudeau M, Charbonneau F, Gelmon K, Laing K, Latreille J, Mackey J, McLeod D, Pritchard K, Provencher L, Verma S (2005) Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol 6(11):886–898. doi:10.1016/S1470-2045(05)70424-1

    Article  CAS  PubMed  Google Scholar 

  9. Miglietta A, Bocca C, Gabriel L (2002) Comparative studies on biological activity of certain microtubule-interacting taxanes. Chem Biol Interact 139(3):283–299

    Article  CAS  PubMed  Google Scholar 

  10. Fromes Y, Gounon P, Veitia R, Bissery MC, Fellous A (1996) Influence of microtubule-associated proteins on the differential effects of paclitaxel and docetaxel. J Protein Chem 15(4):377–388

    Article  CAS  PubMed  Google Scholar 

  11. Jones SE, Savin MA, Holmes FA, O’Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippen JE, Bordelon JH, Kirby R, Sandbach J, Hyman WJ, Khandelwal P, Negron AG, Richards DA, Anthony SP, Mennel RG, Boehm KA, Meyer WG, Asmar L (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24(34):5381–5387. doi:10.1200/JCO.2006.06.5391

    Article  CAS  PubMed  Google Scholar 

  12. Bria E, Giannarelli D, Felici A, Peters WP, Nistico C, Vanni B, Cuppone F, Cognetti F, Terzoli E (2005) Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma. Cancer 103(4):672–679. doi:10.1002/cncr.20757

    Article  CAS  PubMed  Google Scholar 

  13. Bria E, Nistico C, Cuppone F, Carlini P, Ciccarese M, Milella M, Natoli G, Terzoli E, Cognetti F, Giannarelli D (2006) Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer 106(11):2337–2344. doi:10.1002/cncr.21886

    Article  CAS  PubMed  Google Scholar 

  14. De Laurentiis M, Cancello G, D’Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L, Pennacchio R, Criscitiello C, Montanino A, Limite G, Bianco AR, De Placido S (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26(1):44–53. doi:10.1200/JCO.2007.11.3787

    Article  PubMed  Google Scholar 

  15. Boccardo F, Amadori D, Guglielmini P, Sismondi P, Farris A, Agostara B, Gambi A, Catalano G, Faedi M, Rubagotti A (2010) Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer. Oncology 78(3–4):274–281. doi:10.1159/000315735

    Article  CAS  PubMed  Google Scholar 

  16. Burnell M, Levine MN, Chapman JA, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, O’Brien P, Shepherd LE (2010) Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol 28(1):77–82. doi:10.1200/JCO.2009.22.1077

    Article  CAS  PubMed  Google Scholar 

  17. Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O’Reilly S, Verrill M, Smith I, Yarnold J, Coleman R, Earl H, Canney P, Twelves C, Poole C, Bloomfield D, Hopwood P, Johnston S, Dowsett M, Bartlett JM, Ellis I, Peckitt C, Hall E, Bliss JM (2009) Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 373(9676):1681–1692. doi:10.1016/S0140-6736(09)60740-6

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Francis P, Crown J, Di Leo A, Buyse M, Balil A, Andersson M, Nordenskjold B, Lang I, Jakesz R, Vorobiof D, Gutierrez J, van Hazel G, Dolci S, Jamin S, Bendahmane B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Piccart-Gebhart M (2008) Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02–98 randomized trial. J Natl Cancer Inst 100(2):121–133. doi:10.1093/jnci/djm287

    Article  CAS  PubMed  Google Scholar 

  19. Gianni L, Baselga J, Eiermann W, Porta VG, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Cussac AL, Bozhok A, Martinez-Agullo A, Greco M, Byakhov M, Lopez JJ, Mansutti M, Valagussa P, Bonadonna G (2009) Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol 27(15):2474–2481. doi:10.1200/JCO.2008.19.2567

    Article  CAS  PubMed  Google Scholar 

  20. Goldstein LJ, O’Neill A, Sparano JA, Perez EA, Shulman LN, Martino S, Davidson NE (2008) Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 26(25):4092–4099. doi:10.1200/JCO.2008.16.7841

    Article  CAS  PubMed  Google Scholar 

  21. Martin M, Rodriguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munarriz B, Rodriguez CA, Crespo C, de Alava E, Lopez Garcia-Asenjo JA, Guitian MD, Almenar S, Gonzalez-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Segui MA, Mayordomo JI, Anton A, Baena JM, Plazaola A, Modolell A, Pelegri A, Mel JR, Aranda E, Adrover E, Alvarez JV, Garcia Puche JL, Sanchez-Rovira P, Gonzalez S, Lopez-Vega JM (2008) Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst 100(11):805–814. doi:10.1093/jnci/djn151

    Article  CAS  PubMed  Google Scholar 

  22. Martin M, Segui MA, Anton A, Ruiz A, Ramos M, Adrover E, Aranda I, Rodriguez-Lescure A, Grosse R, Calvo L, Barnadas A, Isla D, Martinez del Prado P, Ruiz Borrego M, Zaluski J, Arcusa A, Munoz M, Lopez Vega JM, Mel JR, Munarriz B, Llorca C, Jara C, Alba E, Florian J, Li J, Lopez Garcia-Asenjo JA, Saez A, Rios MJ, Almenar S, Peiro G, Lluch A (2010) Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med 363(23):2200–2210. doi:10.1056/NEJMoa0910320

    Article  CAS  PubMed  Google Scholar 

  23. Polyzos A, Malamos N, Boukovinas I, Adamou A, Ziras N, Kalbakis K, Kakolyris S, Syrigos K, Papakotoulas P, Kouroussis C, Karvounis N, Vamvakas L, Christophyllakis C, Athanasiadis A, Varthalitis I, Georgoulias V, Mavroudis D (2010) FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Res Treat 119(1):95–104. doi:10.1007/s10549-009-0468-0

    Article  CAS  PubMed  Google Scholar 

  24. Roche H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, Symann M, Kerbrat P, Soulie P, Eichler F, Viens P, Monnier A, Vindevoghel A, Campone M, Goudier MJ, Bonneterre J, Ferrero JM, Martin AL, Geneve J, Asselain B (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 24(36):5664–5671. doi:10.1200/JCO.2006.07.3916

    Article  CAS  PubMed  Google Scholar 

  25. Michaud LB (2008) Treatment-experienced breast cancer. Am J Health Syst Pharm 65(10 Supplement 3):S4–S9

    Article  PubMed  Google Scholar 

  26. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor–positive breast cancer. J Clin Oncol 24(23):3726–3734

    Article  CAS  PubMed  Google Scholar 

  27. Lee CW, Chi KN (2000) The standard of reporting of health-related quality of life in clinical cancer trials. J Clin Epidemiol 53(5):451–458

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

We wish to express our warm thanks to Fenghe (Shanghai) Information Technology Co., Ltd. Their help about the data analysis gave a valuable added dimension to our research.

Conflict of Interest

The authors all declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Breast Surgery, Yiwu Maternity and Child Care Hospital, Yiwu, 322000, China

    Qing-jing Feng & Xiao-yun Huang

  2. Department of Surgery, Women’s Hospital, School of Medicine, Zhejiang University, No. 1 Xueshi Road, Hangzhou, 310006, China

    Feng Zhang

  3. Department of Breast Surgery, The International Peace Maternity and Child Health Hospital of China welfare Institute, Shanghai Jiao Tong University, Shanghai, 200030, China

    Zhi-xiang Wu

Authors
  1. Qing-jing Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Feng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiao-yun Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhi-xiang Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Feng Zhang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Feng, Qj., Zhang, F., Huang, Xy. et al. Effectiveness and Complications of Anthracycline and Taxane in the Therapy of Breast Cancer: A Meta-analysis. Pathol. Oncol. Res. 20, 179–184 (2014). https://doi.org/10.1007/s12253-013-9681-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-013-9681-6

Keywords

Search

Navigation